CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials
Category: #health  By Saipriya Iyer  Date: 2020-09-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials

The Chinese pharmaceutical firms are planning to enroll 50,000 candidates from different countries in the Phase 3 trials of COVID-19 vaccine

China National Biotec Group (CNBG) has recently announced that nearly 50,000 patients from across various countries will be enrolled in Phase 3 clinical studies of its COVID-19 vaccine. The Chinese biotechnology firm said in a statement that its lead COVID-19 vaccine candidate will be tested in countries like Bahrain, UAE, Peru, Morocco, Argentina among others.

Both Sinovac Biotech Ltd. and CNBG have revealed that they each have come across two more nations to conduct their late-stage clinical tests. While Pakistan and Serbia have agreed to take part in CNBG’s study, countries like Bangladesh and Turkey have decided to go with Sinovac’s vaccine trials as China decides to boost its efforts to attain an effective vaccine for COVID-19.

As per international media reports, Serbia will test two CNBG vaccines that are being developed in Beijing and Wuhan. Meanwhile, Pakistan is planning to test the vaccine from the laboratory of the Beijing unit.

Speaking on the move, Zhang Yuntao, Vice President, CNBG, said that apart from the active involvement from nearly 10 countries in its Phase 3 clinical studies, the company has also received an overwhelming response from various other foreign countries, with cumulative orders racking up to 500 million doses of its vaccines.

However, CNBG at this point can produce around 300 million doses of its lead vaccine candidate per year. This number is anticipated to be attainable after the overhaul of its existing manufacturing techniques.

As for Dr. Soumya Swaminathan, Chief Scientist, World Health Organization (WHO), the global distribution of the coronavirus vaccine on a large scale will likely take place by the second quarter or third quarter of 2021. By then, countries might see doses flowing in their healthcare sectors to initiate immunization of their population

Source Credit: https://www.republicworld.com/world-news/china/covid-19-vaccine-phase-3-clinical-trial-developed-by-china-to-include.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Vela Diagnostics gains EUA for ViroKey™ SARS-CoV-2 RT-PCR test v2.0
Vela Diagnostics gains EUA for ViroKey™ SARS-CoV-2 RT-PCR test v2.0
By Saipriya Iyer

Vela Diagnostics has recently announced that the U.S. FDA has granted an EUA (Emergency Use Authorization) for its ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 in the United States. This automated p...

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...